The IASLC 2024 Hot Topic in Basic & Translational Science Meeting: Tolerance & Resistance to Targeted Therapy in NSCLC (HTTR 2024) meeting serves as a dynamic platform to exchange groundbreaking research, address field-specific challenges, and foster collaborative ventures across academia and industry. With a focus on advancing our comprehension and management of non-small cell lung cancer within the realm of targeted therapy, our gathering promises to ignite innovative discussions and forge meaningful connections to propel scientific progress.
Goals & Objectives of HTTR 2024:
- Understanding Mechanisms: Basic scientists will present their research findings on the molecular and cellular mechanisms underlying tolerance and resistance to targeted therapies as well as the mechanisms for persistent cells and treatment-induced lineage plasticity in non-small cell lung cancer with oncogenic addiction. This could include identifying key signaling pathways, genetic mutations, or cellular processes involved in treatment response, resistance and persistence.
- Biomarker Discovery: Scientists will discuss the discovery and validation of potential biomarkers of drug tolerant persistence and resistance to targeted therapies. This information is crucial for developing personalized treatment strategies and improving patient stratification.
- Preclinical Models: Researchers will explore the establishment of novel models and preclinical studies using animal models or in vitro systems to simulate and study clinical drug tolerance, persistence, and resistance mechanisms. These models help in the development and/or testing of new therapeutic strategies and understanding the biological basis of treatment failure.
- Drug Development: The meeting will explore ongoing efforts in developing new targeted therapies or combination strategies to overcome resistance to targeted therapy in NSCLC with oncogenic addiction. Basic scientists could present early-stage drug development projects and discuss their potential clinical implications.
- Translational Insights: The translational aspect involves bridging the gap between basic research and clinical applications. Scientists will share how their findings can be translated into clinical interventions, potentially leading to new treatment modalities or therapeutic strategies.
- Collaboration Opportunities: Basic and translational scientists will invite collaborations with clinicians and industry partners to further validate their findings in clinical settings. This collaborative approach can accelerate the translation of basic science discoveries into effective clinical interventions.
- Challenges and Solutions: Scientists may share the challenges they face in their research, such as issues related to drug resistance or limitations of current experimental models. Brainstorming sessions could focus on finding innovative solutions and potential avenues for future research.
The multidisciplinary nature of the audience reflects the comprehensive approach required to address the complexities of tolerance and resistance to targeted therapy in non-small cell lung cancer. The meeting aims to foster collaboration and knowledge exchange among professionals with different expertise to advance the understanding and treatment of NSCLC.
- Basic Scientists: Researchers engaged in basic science research, molecular biology, genetics, and cellular biology, with a focus on understanding the mechanisms of tolerance and resistance to targeted therapies in NSCLC with oncogenic addiction.
- Translational Researchers: Scientists who work on translating basic research findings into clinical applications. They bridge the gap between laboratory discoveries and their practical implementation in patient care.
- Oncologists, pulmonologists, radiation oncologists and other clinicians: Medical professionals specializing in oncology, particularly those who treat patients with non-small cell lung cancer. They would be interested in understanding the latest research findings and clinical implications related to targeted therapy.
- Pathologists and molecular biologists: Pathologists specializing in lung cancer pathology and molecular biologists may attend to gain insights into the molecular characteristics of NSCLC tumors and how these characteristics relate to treatment responses.
- Radiologists: Professionals involved in imaging and radiology, as they play a crucial role in monitoring treatment responses and evaluating disease progression in NSCLC patients undergoing targeted therapy.
- Clinical Trial Investigators: Professionals involved in designing and conducting clinical trials related to targeted therapies in NSCLC. The meeting could provide insights into optimizing trial designs and patient stratification.
- Pharmaceutical and Biotech Professionals: Representatives including researchers from pharmaceutical and biotechnology companies involved in developing targeted therapies for NSCLC. They would be interested in both the scientific aspects and potential research collaborations.
- Healthcare Administrators and Policy Makers: Individuals responsible for healthcare administration and policy decisions may attend to gain insights into emerging therapies and their potential impact on healthcare delivery.
- Patient Advocates: Advocates for lung cancer patients who may attend to learn about advancements in targeted therapies and how they can positively impact patient outcomes.
- Academic Researchers and Students: Scholars and students in the fields of oncology, molecular biology, and related disciplines, who are interested in learning about the latest developments in NSCLC research.
At HTTR 2024, expect a stimulating array of presentation topics encompassing the intricate molecular and cellular mechanisms governing treatment response and resistance to targeted therapies. Delve into the dynamics of persistent cells and treatment-induced lineage plasticity, as well as the discovery and validation of potential biomarkers for drug-tolerant persistence. Explore the fascinating realm of cancer evolution and engage with novel preclinical models aimed at deciphering drug tolerance and resistance mechanisms. Witness the unveiling of early-stage drug development strategies targeting NSCLC with oncogenic addiction, poised to revolutionize clinical practice. Discover the seamless integration of basic research and clinical applications, with discussions on collaborative opportunities between scientists, clinicians, and industry partners. Contemplate the consequences of intratumor heterogeneity and participate in brainstorming sessions aimed at charting innovative pathways for future research. Plus, seize the opportunity for mid-career development, fostering growth for both basic and translational researchers. Join us at HTTR 2024 for an inspiring exploration of cutting-edge science and collaborative breakthroughs.
The IASLC 2024 Hot Topic in Basic & Translational Science Meeting: Tolerance & Resistance to Targeted Therapy in NSCLC (HTTR 2024) meeting serves as a dynamic platform to exchange groundbreaking research, address field-specific challenges, and foster collaborative ventures across academia and industry. With a focus on advancing our comprehension and management of non-small cell lung cancer within the realm of targeted therapy, our gathering promises to ignite innovative discussions and forge meaningful connections to propel scientific progress.
Goals & Objectives of HTTR 2024:
- Understanding Mechanisms: Basic scientists will present their research findings on the molecular and cellular mechanisms underlying tolerance and resistance to targeted therapies as well as the mechanisms for persistent cells and treatment-induced lineage plasticity in non-small cell lung cancer with oncogenic addiction. This could include identifying key signaling pathways, genetic mutations, or cellular processes involved in treatment response, resistance and persistence.
- Biomarker Discovery: Scientists will discuss the discovery and validation of potential biomarkers of drug tolerant persistence and resistance to targeted therapies. This information is crucial for developing personalized treatment strategies and improving patient stratification.
- Preclinical Models: Researchers will explore the establishment of novel models and preclinical studies using animal models or in vitro systems to simulate and study clinical drug tolerance, persistence, and resistance mechanisms. These models help in the development and/or testing of new therapeutic strategies and understanding the biological basis of treatment failure.
- Drug Development: The meeting will explore ongoing efforts in developing new targeted therapies or combination strategies to overcome resistance to targeted therapy in NSCLC with oncogenic addiction. Basic scientists could present early-stage drug development projects and discuss their potential clinical implications.
- Translational Insights: The translational aspect involves bridging the gap between basic research and clinical applications. Scientists will share how their findings can be translated into clinical interventions, potentially leading to new treatment modalities or therapeutic strategies.
- Collaboration Opportunities: Basic and translational scientists will invite collaborations with clinicians and industry partners to further validate their findings in clinical settings. This collaborative approach can accelerate the translation of basic science discoveries into effective clinical interventions.
- Challenges and Solutions: Scientists may share the challenges they face in their research, such as issues related to drug resistance or limitations of current experimental models. Brainstorming sessions could focus on finding innovative solutions and potential avenues for future research.
The multidisciplinary nature of the audience reflects the comprehensive approach required to address the complexities of tolerance and resistance to targeted therapy in non-small cell lung cancer. The meeting aims to foster collaboration and knowledge exchange among professionals with different expertise to advance the understanding and treatment of NSCLC.
- Basic Scientists: Researchers engaged in basic science research, molecular biology, genetics, and cellular biology, with a focus on understanding the mechanisms of tolerance and resistance to targeted therapies in NSCLC with oncogenic addiction.
- Translational Researchers: Scientists who work on translating basic research findings into clinical applications. They bridge the gap between laboratory discoveries and their practical implementation in patient care.
- Oncologists, pulmonologists, radiation oncologists and other clinicians: Medical professionals specializing in oncology, particularly those who treat patients with non-small cell lung cancer. They would be interested in understanding the latest research findings and clinical implications related to targeted therapy.
- Pathologists and molecular biologists: Pathologists specializing in lung cancer pathology and molecular biologists may attend to gain insights into the molecular characteristics of NSCLC tumors and how these characteristics relate to treatment responses.
- Radiologists: Professionals involved in imaging and radiology, as they play a crucial role in monitoring treatment responses and evaluating disease progression in NSCLC patients undergoing targeted therapy.
- Clinical Trial Investigators: Professionals involved in designing and conducting clinical trials related to targeted therapies in NSCLC. The meeting could provide insights into optimizing trial designs and patient stratification.
- Pharmaceutical and Biotech Professionals: Representatives including researchers from pharmaceutical and biotechnology companies involved in developing targeted therapies for NSCLC. They would be interested in both the scientific aspects and potential research collaborations.
- Healthcare Administrators and Policy Makers: Individuals responsible for healthcare administration and policy decisions may attend to gain insights into emerging therapies and their potential impact on healthcare delivery.
- Patient Advocates: Advocates for lung cancer patients who may attend to learn about advancements in targeted therapies and how they can positively impact patient outcomes.
- Academic Researchers and Students: Scholars and students in the fields of oncology, molecular biology, and related disciplines, who are interested in learning about the latest developments in NSCLC research.
At HTTR 2024, expect a stimulating array of presentation topics encompassing the intricate molecular and cellular mechanisms governing treatment response and resistance to targeted therapies. Delve into the dynamics of persistent cells and treatment-induced lineage plasticity, as well as the discovery and validation of potential biomarkers for drug-tolerant persistence. Explore the fascinating realm of cancer evolution and engage with novel preclinical models aimed at deciphering drug tolerance and resistance mechanisms. Witness the unveiling of early-stage drug development strategies targeting NSCLC with oncogenic addiction, poised to revolutionize clinical practice. Discover the seamless integration of basic research and clinical applications, with discussions on collaborative opportunities between scientists, clinicians, and industry partners. Contemplate the consequences of intratumor heterogeneity and participate in brainstorming sessions aimed at charting innovative pathways for future research. Plus, seize the opportunity for mid-career development, fostering growth for both basic and translational researchers. Join us at HTTR 2024 for an inspiring exploration of cutting-edge science and collaborative breakthroughs.
Detailed program
The multidisciplinary nature of the audience reflects the comprehensive approach required to address the complexities of tolerance and resistance to targeted therapy in non-small cell lung cancer. The meeting aims to foster collaboration and knowledge exchange among professionals with different expertise to advance the understanding and treatment of NSCLC.
- Basic Scientists: Researchers engaged in basic science research, molecular biology, genetics, and cellular biology, with a focus on understanding the mechanisms of tolerance and resistance to targeted therapies in NSCLC with oncogenic addiction.
- Translational Researchers: Scientists who work on translating basic research findings into clinical applications. They bridge the gap between laboratory discoveries and their practical implementation in patient care.
- Oncologists, pulmonologists, radiation oncologists and other clinicians: Medical professionals specializing in oncology, particularly those who treat patients with non-small cell lung cancer. They would be interested in understanding the latest research findings and clinical implications related to targeted therapy.
- Pathologists and molecular biologists: Pathologists specializing in lung cancer pathology and molecular biologists may attend to gain insights into the molecular characteristics of NSCLC tumors and how these characteristics relate to treatment responses.
- Radiologists: Professionals involved in imaging and radiology, as they play a crucial role in monitoring treatment responses and evaluating disease progression in NSCLC patients undergoing targeted therapy.
- Clinical Trial Investigators: Professionals involved in designing and conducting clinical trials related to targeted therapies in NSCLC. The meeting could provide insights into optimizing trial designs and patient stratification.
- Pharmaceutical and Biotech Professionals: Representatives including researchers from pharmaceutical and biotechnology companies involved in developing targeted therapies for NSCLC. They would be interested in both the scientific aspects and potential research collaborations.
- Healthcare Administrators and Policy Makers: Individuals responsible for healthcare administration and policy decisions may attend to gain insights into emerging therapies and their potential impact on healthcare delivery.
- Patient Advocates: Advocates for lung cancer patients who may attend to learn about advancements in targeted therapies and how they can positively impact patient outcomes.
- Academic Researchers and Students: Scholars and students in the fields of oncology, molecular biology, and related disciplines, who are interested in learning about the latest developments in NSCLC research.